Recent reports suggested that eIF3a could mediate glycolytic metabolism, and the level of anti-eIF3A autoantibody in serum may represent a potential diagnostic marker for hepatocellular carcinoma (Heo et al., 2019; Miao et al., 2019). This evidence concerns the gene EIF3A and hepatocellular carcinoma.